Skip to main content
. Author manuscript; available in PMC: 2019 Jun 12.
Published in final edited form as: Lancet Oncol. 2018 Jul 11;19(8):1082–1093. doi: 10.1016/S1470-2045(18)30350-4

Table 3:

Pazopanib pharmacokinetics in the dose expansion cohort

Mean (SD) Median Range Number of observations
Cmax, steady state (μg/mL) 51·0 (13·9) 57·6 31·7–66·6 7
Tmax, steady state (h) 3·3 (1·4) 3·0 2·0–6·0 7
Cmin, steady state (μg/mL) 35·9 (5·5) 36·8 28·8–41·5 5
AUC0–24 h, steady state (h × mg/L) 1080·7 (144·9) 1114·2 877·6–1216·7 4
Ke (per h) 0·02 (0·01) 0·02 0·02–0·03 4
T1/2 (h) 31·9 (6·4) 33·0 23·1–38·5 4
Clearance steady state/bioavailability (L/h) 0·74 (0·13) 0·7 0·6–0·9 4
Vz, steady state bioavailability (L/kg) 0·7 (0·1) 0·7 0·6–0·8 4

Pharmacokinetics analyses were done in the nine patients recruited in the dose expansion phase who received the recommended phase 2 dose of combination therapy. All patients received pazopanib at the indicated doses plus weekly cetuximab. Cmax=maximum plasma concentration. Tmax=time to reach the maximum plasma concentration. Cmin=minimum concentration. AUC=area under the curve. Ke=elimination rate constant. T1/2=half-life. Vz=volume of distribution.